Related Experiment Video
Updated: May 12, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism
Fernando Lizcano1, Diana Vargas
1Biomedical Research Center, Universidad de La Sabana, Chía, Colombia.
Abstract:
The PPARγ nuclear receptor regulates the expression of genes involved in lipid and carbohydrate metabolism, and it has protective effects in some patients with type 2 diabetes. Nevertheless, the therapeutic value of the PPARγ nuclear receptor protein is limited due to the secondary effects of some PPARγ ligands. Because the downstream effects of PPARγ are determined by the binding of specific cofactors that are mediated by ligand-induced conformational changes, we evaluated the differential effects of various ligands on the binding of certain cofactors associated with PPARγ. The ligands used were rosiglitazone for treating type 2 diabetes and telmisartan for treating arterial hypertension. Functional, phenotypic, and molecular studies were conducted on pre-adipocyte 3T3-L1 and functional studies in U2OS cells. The moderating influence of various cofactor families was evaluated using transient transfection assays. Our findings confirm that telmisartan has a partial modulating effect on PPARγ activity compared to rosiglitazone. The cofactors SRC1 and GRIP1 mediate the activity of telmisartan and rosiglitazone and partially determine the difference in their effects. Studying the modulating activity of these cofactors can provide interesting insights for developing new therapeutic approaches for certain metabolic diseases.
Insights
Telmisartan partially modulates PPARγ activity differently than rosiglitazone, with cofactors SRC1 and GRIP1 mediating these effects. This finding offers insights for developing new metabolic disease therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Endocrinology
Background:
- Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor regulating lipid and carbohydrate metabolism, showing protective effects in type 2 diabetes.
- Therapeutic use of PPARγ is limited by secondary effects of its ligands.
- Ligand-induced conformational changes in PPARγ dictate downstream effects through cofactor binding.
Purpose of the Study:
- To investigate the differential effects of various ligands on PPARγ cofactor binding.
- To compare the effects of rosiglitazone (type 2 diabetes) and telmisartan (arterial hypertension) on PPARγ activity.
- To identify cofactors mediating ligand-specific PPARγ modulation.
Main Methods:
- Functional, phenotypic, and molecular studies were performed on pre-adipocyte 3T3-L1 cells.
- Functional studies were conducted in U2OS cells.
- Transient transfection assays were used to evaluate cofactor family influence on PPARγ.
Main Results:
- Telmisartan demonstrated a partial modulating effect on PPARγ activity compared to rosiglitazone.
- Cofactors Steroid Receptor Coactivator 1 (SRC1) and Glucocorticoid Receptor Interacting Protein 1 (GRIP1) were identified as mediators of telmisartan and rosiglitazone activity.
- These cofactors partially explain the differential effects observed between the two ligands.
Conclusions:
- Telmisartan exhibits partial agonism at PPARγ, distinct from the effects of rosiglitazone.
- SRC1 and GRIP1 play a crucial role in mediating the differential activities of PPARγ ligands.
- Understanding cofactor modulation of PPARγ offers potential for developing targeted therapies for metabolic diseases.
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Master Transcription Regulators
Master Transcription Regulators
Cooperative Binding of Transcription Regulators
